|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, July 26, 2017 ) According to the recently published report 'Receptor Tyrosine Protein Kinase ERBB 3-Pipeline Review H2 2017'; Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) pipeline Target constitutes close to 23 molecules. Out of which approximately 21 molecules are developed by companies and remaining by the universities/institutes.
Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1)-Receptor tyrosine-protein kinase erbB-3 or HER3 is a membrane bound protein encoded by the ERBB3 gene. It belongs to tyrosine-protein kinase family. It plays an essential role as cell surface receptor for neuregulins. It binds to neuregulin-1 (NRG1) and is activated by it. It also activated by CSPG5.
The report 'Receptor Tyrosine Protein Kinase ERBB 3-Pipeline Review H2 2017' outlays comprehensive information on the Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics complete with analysis by indications stage of development mechanism of action (MoA) route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently The molecules developed by companies in Phase II Phase I IND/CTA Filed Preclinical and Discovery stages are 7 5 2 6 and 1 respectively. Similarly the universities portfolio in Preclinical stages comprises 2 molecules respectively. Report covers products from therapy areas Oncology which include indications Non-Small Cell Lung Cancer Breast Cancer Gastric Cancer Colorectal Cancer Head And Neck Cancer Squamous Cell Carcinoma Solid Tumor Melanoma Metastatic Breast Cancer Lung Cancer Pancreatic Cancer Bladder Cancer Cervical Cancer Esophageal Cancer Hepatocellular Carcinoma Lung Adenocarcinoma Metastatic Colorectal Cancer Ovarian Cancer Recurrent Head And Neck Cancer Squamous Cell Carcinoma Squamous Cell Carcinoma Adenocarcinoma Of The Gastroesophageal Junction Colorectal Tumor Endometrial Cancer Epithelial Tumor Ewing Sarcoma Head And Neck Cancer Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Hypopharyngeal Cancer Laryngeal Cancer Malignant Mesothelioma Metastatic Adenocarcinoma of The Pancreas Metastatic Hepatocellular Carcinoma (HCC) Nasopharyngeal Cancer Neuroendocrine Tumors Oral Cavity (Mouth) Cancer Oropharyngeal Cancer Osteosarcoma Pancreatic Tumor Peritoneal Tumor Skin Cancer Small-Cell Lung Cancer Squamous Non-Small Cell Lung Cancer and Thyroid Cancer.
For more information about this report at http://www.reportsweb.com/receptor-tyrosine-protein-kinase-erbb-3-pipeline-review-h2-2017
Report Scope
- The report provides a snapshot of the global therapeutic landscape for Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1)
- The report reviews Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes product description descriptive MoA R&D brief licensing and collaboration details & other developmental activities
- The report reviews key players involved in Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA) route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001881479/sample
Reasons to buy
- Gain strategically significant competitor information analysis and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Key Company profiles
AstraZeneca Plc
AVEO Pharmaceuticals Inc
Celldex Therapeutics Inc
Daiichi Sankyo Company Ltd
Etubics Corp
F. Hoffmann-La Roche Ltd
GlaxoSmithKline Plc
Hanmi Pharmaceuticals Co Ltd
Hummingbird Bioscience Pte Ltd
ImmunoGen Inc
MediaPharma Srl
Merrimack Pharmaceuticals Inc
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001881479/discount
List of Tables
Number of Products under Development by Stage of Development H2 2017
Number of Products under Development by Therapy Areas H2 2017
Number of Products under Development by Indications H2 2017
Number of Products under Development by Indications H2 2017 (Contd..1) H2 2017
Number of Products under Development by Indications H2 2017 (Contd..2) H2 2017
Number of Products under Development by Companies H2 2017
Products under Development by Companies H2 2017
Products under Development by Companies H2 2017 (Contd..1) H2 2017
Products under Development by Companies H2 2017 (Contd..2) H2 2017
Products under Development by Companies H2 2017 (Contd..3) H2 2017
Products under Development by Companies H2 2017 (Contd..4) H2 2017
Number of Products under Investigation by Universities/Institutes H2 2017
Products under Investigation by Universities/Institutes H2 2017
Number of Products by Stage and Mechanism of Actions H2 2017
Number of Products by Stage and Route of Administration H2 2017
Number of Products by Stage and Molecule Type H2 2017
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001881479/buy/3500
ReportsWeb.com
Rajat Sahni
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
